Biohaven Pharmaceutical Holding Co. Ltd.
(NYSE : BHVN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. -0.50%43.970.9%$1186.44m
ABBVAbbVie, Inc. -0.22%107.121.9%$1023.77m
JNJJohnson & Johnson -0.23%164.480.7%$988.09m
MRKMerck & Co., Inc. 0.81%73.640.7%$914.30m
LLYEli Lilly & Co. -0.26%231.581.1%$588.95m
BMYBristol-Myers Squibb Co. -0.61%60.261.0%$575.61m
AZNAstraZeneca Plc 1.46%60.351.0%$353.10m
NVSNovartis AG -0.75%82.950.2%$156.40m
CRVSCorvus Pharmaceuticals, Inc. -3.27%6.800.7%$140.27m
GSKGlaxoSmithKline Plc -2.44%38.380.2%$135.32m
RGENRepligen Corp. -0.29%323.266.8%$123.14m
SNYSanofi -1.60%47.940.2%$122.20m
RPRXRoyalty Pharma Plc -0.08%37.100.1%$121.13m
VTRSViatris, Inc. 0.30%13.380.0%$107.54m
NVONovo Nordisk A/S -1.36%100.710.1%$101.76m

Company Profile

Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.